Randomized Phase II trial to evaluate the safety and efficacy of oral vitamin B 12 treatment after total gastrectomy for gastric cancer

Rino Yasushi0 个研究点目标入组 60 人开始时间: 2022年9月12日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1:Histologically proven adenocarcinoma of the stomach and dignosed pathological stage I to III
•2:Received R0 resection
•3:Age at the time of consent is 20 years or older.
•4:ECOG performance status 0-2
•5:seremu vitamin B12 was under 200pg/ml
•6: Sufficient oral intake
•7: Clinical laboratory values within 4 weeks prior to enrollment meet the following criteria to determine that major organ function is preserved.
•a) White blood cell count >=3,000/mm3 and <=12,000mm3
•b) Platelet count >=75,000/mm3
•c) Hemoglobin >=8.0g/dl
•d) AST (GOT), ALT (GPT) <= 100IU/L
•e) Serum total bilirubin <= 1.5mg/dl
•f) Serum creatinine <= 1.5 mg/dl
•8: Able to respond to medication status surveys
•9:Patients were given a written explanation of the study protocol and provided their written informed consent before participating.

•1:Synchronous or metachronous cancer (synchronous multiple cancers in the stomach included).
•2:Allergic reaction to vitamin B12
•3:Systemic treatment with vitamin B12
•4:One of the following comorbidities
•a) Poorly controlled diabetes mellitus
•b) Uncontrolled hypertension
•c) Cirrhosis or liver failure
•d) Renal failure
•e) interstitial pneumonia, pulmonary fibrosis, severe emphysema
•f) Active infection
•g) Heart failure, myocardial infarction, angina pectoris or significant ECG abnormalities within 6 month
•5:Any other medical conditions that made a patient unsuitable for inclusion in the study according to the opinion of the investigator were also considered to be exclusion criteria for this study.

发起方

Rino Yasushi